Drug Trial Radar · NCT06230588
A Clinical Trial of TQH3906 Capsules in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Feb 2, 2024
Primary completion
Apr 27, 2025
Study completion Apr 27, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was divided into three parts: single and multiple dosing and food effect study, which were designed to evaluate the safety and tolerability of TQH3906 capsules administered in single or multiple dose escalation in healthy adult subjects.
Conditions
- Psoriasis
Interventions
TQH3906 capsuleDrug
TQH3906 is a kinase inhibitor.
TQH3906 placeboDrug
Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE)Time frame: Up to 18 days
- Serious Adverse Events (SAE)Time frame: Up to 18 days
- Treatment-emergent adverse events (TEAEs)Time frame: Up to 18 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.